hydroxyprogesterone caproate

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1	32
kinase-selectivity-class	EIF2AK3,GRK2	2
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Preterm premature rupture of membranes	1662.07	70.49	254	7305	1387	90619501
Premature baby	1344.39	70.49	329	7230	24748	90596140
Injection site pruritus	1235.75	70.49	361	7198	53473	90567415
Injection site pain	1176.18	70.49	465	7094	173234	90447654
Premature labour	612.46	70.49	155	7404	13221	90607667
Injection site mass	584.79	70.49	166	7393	21924	90598964
Injection site swelling	568.06	70.49	206	7353	59633	90561255
Uterine contractions during pregnancy	543.71	70.49	85	7474	544	90620344
Product dose omission issue	542.61	70.49	323	7236	291364	90329524
Inappropriate schedule of product administration	512.08	70.49	249	7310	149684	90471204
Product administration error	457.21	70.49	143	7416	26280	90594608
Injection site erythema	420.38	70.49	191	7368	98311	90522577
Injection site nodule	377.28	70.49	85	7474	4388	90616500
Cervical incompetence	326.14	70.49	55	7504	593	90620295
Breech presentation	314.51	70.49	59	7500	1208	90619680
Induced labour	250.56	70.49	47	7512	961	90619927
Shortened cervix	240.21	70.49	37	7522	211	90620677
Injection site rash	239.26	70.49	86	7473	24087	90596801
Amniotic cavity infection	235.29	70.49	47	7512	1349	90619539
Premature separation of placenta	183.53	70.49	42	7517	2320	90618568
Injection site warmth	175.85	70.49	63	7496	17452	90603436
Pre-eclampsia	171.02	70.49	55	7504	10993	90609895
Injection site urticaria	159.29	70.49	59	7500	17952	90602936
Abortion spontaneous	149.22	70.49	78	7481	53978	90566910
Injection site bruising	140.18	70.49	74	7485	52233	90568655
Stillbirth	139.97	70.49	43	7516	7400	90613488
Product prescribing error	136.26	70.49	61	7498	30084	90590804
Cervical dilatation	131.54	70.49	16	7543	3	90620885
Premature delivery	127.56	70.49	63	7496	38699	90582189
Therapy cessation	116.39	70.49	58	7501	36303	90584585
Product administered at inappropriate site	113.26	70.49	32	7527	4119	90616769
Gestational diabetes	109.73	70.49	39	7520	10543	90610345
Limb discomfort	105.22	70.49	55	7504	38005	90582883
Drug ineffective	102.35	70.49	3	7556	1384295	89236593
Nonreassuring foetal heart rate pattern	102.16	70.49	15	7544	58	90620830
Maternal drugs affecting foetus	102.11	70.49	31	7528	5124	90615764
Injection site reaction	88.22	70.49	68	7491	92012	90528876
Pruritus	78.39	70.49	152	7407	541373	90079515
Gestational hypertension	76.32	70.49	22	7537	3040	90617848
Vaginal haemorrhage	74.66	70.49	41	7518	31230	90589658
Cervix cerclage procedure	71.66	70.49	11	7548	61	90620827
Placenta praevia	71.50	70.49	17	7542	1108	90619780

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Preterm premature rupture of membranes	1763.67	76.69	251	5862	1264	110581922
Injection site pain	1104.79	76.69	400	5713	177522	110405664
Injection site pruritus	1099.46	76.69	298	5815	50960	110532226
Premature labour	705.83	76.69	150	5963	9022	110574164
Product dose omission issue	552.00	76.69	293	5820	321489	110261697
Uterine contractions during pregnancy	539.65	76.69	78	6035	439	110582747
Inappropriate schedule of product administration	509.93	76.69	240	5873	203397	110379789
Injection site swelling	507.86	76.69	172	5941	61618	110521568
Injection site mass	493.11	76.69	136	5977	24477	110558709
Injection site erythema	398.71	76.69	161	5952	94015	110489171
Product administration error	375.23	76.69	121	5992	37096	110546090
Breech presentation	370.10	76.69	59	6054	686	110582500
Injection site nodule	362.89	76.69	77	6036	4569	110578617
Cervical incompetence	335.65	76.69	52	6061	495	110582691
Amniotic cavity infection	268.02	76.69	46	6067	861	110582325
Induced labour	260.22	76.69	45	6068	882	110582304
Shortened cervix	246.87	76.69	35	6078	167	110583019
Injection site rash	219.04	76.69	72	6041	23347	110559839
Premature separation of placenta	217.61	76.69	42	6071	1538	110581648
Pre-eclampsia	201.96	76.69	54	6059	8596	110574590
Injection site warmth	168.73	76.69	55	6058	17350	110565836
Injection site urticaria	153.21	76.69	51	6062	17164	110566022
Injection site bruising	144.94	76.69	66	6047	51197	110531989
Abortion spontaneous	132.37	76.69	55	6058	34227	110548959
Gestational diabetes	130.25	76.69	37	6076	7352	110575834
Cervical dilatation	129.33	76.69	15	6098	3	110583183
Premature delivery	127.98	76.69	52	6061	30580	110552606
Product prescribing error	123.14	76.69	59	6054	51272	110531914
Limb discomfort	113.57	76.69	52	6061	40802	110542384
Therapy cessation	96.88	76.69	48	6065	44809	110538377
Vaginal haemorrhage	96.01	76.69	40	6073	25034	110558152
Gestational hypertension	92.18	76.69	22	6091	2212	110580974
Maternal drugs affecting foetus	88.33	76.69	20	6093	1597	110581589
Oligohydramnios	79.50	76.69	22	6091	3972	110579214

Source	Code	Description
ATC	G03DA03	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS Pregnen (4) derivatives
ATC	G03FA02	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, fixed combinations
FDA CS	M0447349	Progesterone Congeners
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D006728	Hormones
MeSH PA	D011372	Progestins
FDA EPC	N0000175602	Progestin
CHEBI has role	CHEBI:25212	metabolite
CHEBI has role	CHEBI:59826	progestin
CHEBI has role	CHEBI:75771	mouse metabolite
CHEBI has role	CHEBI:77746	human metabolite

Disease	Relation	SNOMED_ID	DOID
Prevention of Premature Labor	indication
Endometrial carcinoma	off-label use	254878006	DOID:2871
Impaired glucose tolerance	contraindication	9414007
Jaundice	contraindication	18165001
Depressive disorder	contraindication	35489007
Migraine	contraindication	37796009	DOID:6364
Hypertensive disorder	contraindication	38341003	DOID:10763
Mild pre-eclampsia	contraindication	41114007
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Intermenstrual bleeding - irregular	contraindication	64996003
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Neoplasm of liver	contraindication	126851005	DOID:3571
Deep venous thrombosis	contraindication	128053003
Seizure disorder	contraindication	128613002
Asthma	contraindication	195967001	DOID:2841
Disease of liver	contraindication	235856003	DOID:409
Thromboembolic disorder	contraindication	371039008
Carcinoma of female breast	contraindication	447782002
Predisposition to Thrombosis	contraindication

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

hydroxyprogesterone caproate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN	AGONIST	IC50	7.66	SCIENTIFIC LITERATURE	DRUG LABEL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.26	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.57	DRUG MATRIX
Corticosteroid-binding globulin	Secreted	P08185	CBG_HUMAN		Ki	7.74	CHEMBL
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	7.64	DRUG MATRIX
Mitogen-activated protein kinase 3	Kinase	P27361	MK03_HUMAN		IC50	5.50	DRUG MATRIX
Sex hormone-binding globulin	Secreted	P04278	SHBG_HUMAN		Kd	7	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	6.31	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	8.81	DRUG MATRIX

ID	Source
4017613	VUID
N0000179012	NUI
D00949	KEGG_DRUG
4017613	VANDF
4019781	VANDF
CHEBI:5812	CHEBI
CHEMBL1200848	ChEMBL_ID
DB06789	DRUGBANK_ID
DB14570	DRUGBANK_ID
1087965	RXNORM
179630	MMSL
3385	MMSL
4853	MMSL
7924	MMSL
d00554	MMSL
001291	NDDF
001293	NDDF
126110005	SNOMEDCT_US
126111009	SNOMEDCT_US
56014002	SNOMEDCT_US
C0044971	UMLSCUI
D000077713	MESH_DESCRIPTOR_UI
D019326	MESH_DESCRIPTOR_UI
C0045010	UMLSCUI
633	INN_ID
169870	PUBCHEM_CID
68-96-2	SECONDARY_CAS_RN
6238	PUBCHEM_CID
276F2O42F5	UNII
716	INN_ID
21807M87J2	UNII
CHEBI:17252	CHEBI
21807M87J2	INXIGHT DRUGS
276F2O42F5	INXIGHT DRUGS

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
HYDROXYPROGESTERONE CAPROATE	Human Prescription Drug Label	1	47335-037	INJECTION	250 mg	INTRAMUSCULAR	ANDA	26 sections
Hydroxyprogesterone Caproate	Human Prescription Drug Label	1	55150-311	INJECTION	1250 mg	INTRAMUSCULAR	ANDA	12 sections
Hydroxyprogesterone Caproate	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1797	INJECTION	250 mg	INTRAMUSCULAR	ANDA	24 sections